Countries covered: Indonesia
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts.
Please Note: this is delivered as a Zip file.
Additional Information
In November 2008, the Health Ministry introduced rules requiring drug companies to have production facilities in the country, in order to get licences to sell their products in Indonesia. The rules will affect 13 international companies that sell their products in Indonesia but do not have manufacturing facilities.
The economy is predicted to slow in 2009, expanding at just 3.5% compared to an estimated 6.1% in 2008 largely due to a lower demand for Indonesian exports. The stock market and the Indonesian rupiah took a beating in 2008. The government under president Bambang Susilo Yudhoyono faces the challenge of steadying its currency from further devaluation.
Public sector funding for healthcare is low, estimated at around US$4.4 billion in 2008 and the country continues to rely on international aid. Despite the present administration placing more emphasis on healthcare and funding, the insufficient number of health professionals and bureaucratic problems are hampering development.
Protection of intellectual property rights is generally regarded as inadequate in Indonesia and counterfeiting is also a major problem. Although the government has started to crackdown on distributors of counterfeit drugs, intellectual property protection for pharmaceuticals remains weak. The country remained on the US government’s Watch List in 2008.
The domestic pharmaceutical manufacturing industry is strong and the country has become an attractive base for many multinational producers to operate. This is largely down to a cheap labour force and generally inexpensive production costs.
Espicom estimates a healthy growth rate of around 7.2%, and expects the Indonesian market to surpass the US$2 billion mark for the first time in 2010, reaching US$2.5 billion by 2013, although per capita spending will remain low, at around US$10.
Related Reports:
Snapshots Hungary Pharmaceuticals 2009
Snapshots Poland Pharmaceuticals 2009
Snapshots South Africa Pharmaceuticals 2009
Snapshots Spain Pharmaceuticals 2009
Snapshots Venezuela Pharmaceuticals 2009
Mapping the Healthcare Landscape Bringing pharmaceuticals into focus
Australia Pharmaceuticals and Healthcare Report Q1 2010
Thailand Pharmaceuticals and Healthcare Report Q1 2010
Poland Pharmaceuticals and Healthcare Report Q1 2010
Argentina Pharmaceuticals and Healthcare Report Q1 2010
|
(0 items)
